These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 23814052)

  • 41. Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients.
    Liu B; Chen S; Guan Y; Chen L
    PLoS One; 2015; 10(7):e0133800. PubMed ID: 26193702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
    Dolniak B; Katsoulidis E; Carayol N; Altman JK; Redig AJ; Tallman MS; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Platanias LC
    J Biol Chem; 2008 May; 283(18):12034-42. PubMed ID: 18299328
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mouse models of myeloproliferative neoplasms: JAK of all grades.
    Li J; Kent DG; Chen E; Green AR
    Dis Model Mech; 2011 May; 4(3):311-7. PubMed ID: 21558064
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer.
    Hu K; Zhang J; Yu M; Xiong C
    Future Oncol; 2017 Mar; 13(6):489-498. PubMed ID: 27785922
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of the Akt pathway in mRNA translation of interferon-stimulated genes.
    Kaur S; Sassano A; Dolniak B; Joshi S; Majchrzak-Kita B; Baker DP; Hay N; Fish EN; Platanias LC
    Proc Natl Acad Sci U S A; 2008 Mar; 105(12):4808-13. PubMed ID: 18339807
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Anti-angiogenic effect of interferon on JAK2V617F positive myeloproliferative neoplasms and its anti-angiogenic mechanisms].
    Fu J; Xu Q; Zhao Y; Liu G; Cheng Z; Liang W; Xie X; Gu L
    Zhonghua Yi Xue Za Zhi; 2015 Dec; 95(46):3727-32. PubMed ID: 26850010
    [TBL] [Abstract][Full Text] [Related]  

  • 48. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
    Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
    Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
    [TBL] [Abstract][Full Text] [Related]  

  • 49. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation.
    Lin X; Rice KL; Buzzai M; Hexner E; Costa FF; Kilpivaara O; Mullally A; Soares MB; Ebert BL; Levine R; Licht JD
    Leukemia; 2013 Feb; 27(2):344-52. PubMed ID: 22864358
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutant calreticulin in myeloproliferative neoplasms.
    How J; Hobbs GS; Mullally A
    Blood; 2019 Dec; 134(25):2242-2248. PubMed ID: 31562135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
    Liu Z; Li Y; Lv C; Wang L; Song H
    Biochem Biophys Res Commun; 2016 Sep; 478(2):893-9. PubMed ID: 27520370
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mnk mediates integrin α6β4-dependent eIF4E phosphorylation and translation of VEGF mRNA.
    Korneeva NL; Soung YH; Kim HI; Giordano A; Rhoads RE; Gram H; Chung J
    Mol Cancer Res; 2010 Dec; 8(12):1571-8. PubMed ID: 21047768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons.
    Lekmine F; Uddin S; Sassano A; Parmar S; Brachmann SM; Majchrzak B; Sonenberg N; Hay N; Fish EN; Platanias LC
    J Biol Chem; 2003 Jul; 278(30):27772-80. PubMed ID: 12759354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening.
    Mishra RK; Clutter MR; Blyth GT; Kosciuczuk EM; Blackburn AZ; Beauchamp EM; Schiltz GE; Platanias LC
    Chem Biol Drug Des; 2019 Oct; 94(4):1813-1823. PubMed ID: 31260185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cyclin-dependent kinase activity is required for type I interferon production.
    Cingöz O; Goff SP
    Proc Natl Acad Sci U S A; 2018 Mar; 115(13):E2950-E2959. PubMed ID: 29507205
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.
    Parmar S; Smith J; Sassano A; Uddin S; Katsoulidis E; Majchrzak B; Kambhampati S; Eklund EA; Tallman MS; Fish EN; Platanias LC
    Blood; 2005 Oct; 106(7):2436-43. PubMed ID: 15790787
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
    Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
    Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
    Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ISG12a inhibits HCV replication and potentiates the anti-HCV activity of IFN-α through activation of the Jak/STAT signaling pathway independent of autophagy and apoptosis.
    Chen Y; Jiao B; Yao M; Shi X; Zheng Z; Li S; Chen L
    Virus Res; 2017 Jan; 227():231-239. PubMed ID: 27777077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Geyer HL; Mesa RA
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.